denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Hodgkin lymphoma, Adult, Epidemiology, Clinical Practice (Health Services and Quality), Autoimmune hemolytic anemia, Lymphomas, Non-Hodgkin lymphoma, Drug development, Clinical Research, Health outcomes research, Genetic Disorders, B Cell lymphoma, Education, Pediatric, Diseases, Immune Disorders, Immunodeficiency, Real-world evidence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Session: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Hodgkin lymphoma, Adult, Epidemiology, Clinical Practice (Health Services and Quality), Autoimmune hemolytic anemia, Lymphomas, Non-Hodgkin lymphoma, Drug development, Clinical Research, Health outcomes research, Genetic Disorders, B Cell lymphoma, Education, Pediatric, Diseases, Immune Disorders, Immunodeficiency, Real-world evidence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024, 9:30 AM-10:45 AM
Disclosures: Rao: Pharming: Research Funding.
See more of: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
See more of: Education Program
See more of: Education Program
Previous Presentation
|
Next Presentation >>